These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12061328)

  • 1. High doses of riboflavin and thiamine may help in secondary prevention of hyperlactatemia.
    McComsey GA; Lederman MM
    AIDS Read; 2002 May; 12(5):222-4. PubMed ID: 12061328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riboflavin treatment of antiretroviral induced lactic acidosis and hepatic steatosis.
    Posteraro AF; Mauriello M; Winter SM
    Conn Med; 2001 Jul; 65(7):387-90. PubMed ID: 11508132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.
    Bolhaar MG; Karstaedt AS
    Clin Infect Dis; 2007 Jul; 45(2):254-60. PubMed ID: 17578788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.
    Hwang SW; Leo YS
    Singapore Med J; 2001 Jun; 42(6):247-51. PubMed ID: 11547960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
    Dieterich DT
    AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
    Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
    Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
    Lonergan JT; Barber RE; Mathews WC
    AIDS; 2003 Nov; 17(17):2495-9. PubMed ID: 14600521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.
    Bonnet F; Bonarek M; Morlat P; Mercié P; Dupon M; Gemain MC; Malvy D; Bernard N; Pellegrin JL; Beylot J
    Clin Infect Dis; 2003 May; 36(10):1324-8. PubMed ID: 12746780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactic acidemia in infection with human immunodeficiency virus.
    Carr A
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S96-S100. PubMed ID: 12652378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic hyperlactatemia in a patient on nucleoside reverse transcriptase inhibitors.
    Ball SC
    AIDS Read; 2001 Dec; 11(12):593-5. PubMed ID: 11806170
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting.
    Manosuthi W; Prasithsirikul W; Chumpathat N; Suntisuklappon B; Athichathanabadi C; Chimsuntorn S; Sungkanuparph S
    Int J Infect Dis; 2008 Nov; 12(6):582-6. PubMed ID: 18337140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.
    Calza L; Manfredi R; Chiodo F
    Clin Nutr; 2005 Feb; 24(1):5-15. PubMed ID: 15681097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors.
    Boffito M; Marietti G; Audagnotto S; Raiter R; Di Perri G
    Clin Infect Dis; 2002 Feb; 34(4):558-9. PubMed ID: 11797190
    [No Abstract]   [Full Text] [Related]  

  • 15. [Fatty liver and serum lactate elevation in an HIV patient--is the routine determination of thiamine and riboflavin during HAART useful?].
    Koch HJ
    Dtsch Med Wochenschr; 2003 May; 128(20):1134; author reply 1134. PubMed ID: 12748905
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal lactic acidosis during antiretroviral therapy.
    Rey C; Prieto S; Medina A; Pérez C; Concha A; Menéndez S
    Pediatr Crit Care Med; 2003 Oct; 4(4):485-7. PubMed ID: 14525648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors].
    Pedrol E; Ribell M; Deig E; Villà Mdel C; Miró O; Garrabou G; Soler A
    Med Clin (Barc); 2005 Jul; 125(6):201-4. PubMed ID: 16022831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production.
    Nerurkar PV; Pearson L; Frank JE; Yanagihara R; Nerurkar VR
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1205-11. PubMed ID: 14983988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.
    McComsey G
    AIDS Rev; 2002; 4(3):140-7. PubMed ID: 12416448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy.
    Patel V; Hedayati SS
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):109-14; quiz 115. PubMed ID: 16932402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.